Cardiac risk factors and adverse events among patients receiving first-line CLL treatment in a real-world community practice setting.

被引：0

作者：

Mato, Anthony R.

Tang, Boxiong

Azmi, Soraya

Yang, Keri

Wallis, Nicola

Stern, Jennifer C.

Hedrick, Eric

Huang, Jane

Sharman, Jeff Porter

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] BeiGene Ltd, Emeryville, CA USA

[3] BeiGene USA Inc, San Mateo, CA USA

[4] BeiGene Ltd, Cambridge, MA USA

[5] Willamette Valley Canc Inst, Eugene, OR USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.e24044

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e24044

引用

页数：3

共 50 条

[41] Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.
Geynisman, Daniel M.
Kish, Jonathan K.
Falkenstein, Angelica
Huo, Stephen
Del Tejo, Viviana
Rosenblatt, Lisa
Guttenplan, Sarah
Balanean, Alexandrina
Feinberg, Bruce A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[42] Patterns and risk factors of immune-related adverse events in a real-world cohort with lung cancer receiving immunotherapy
Hu, Xiao
Gurinovich, Anastasia
Pan, Stacey
Salei, Yana
Lin, Jeffrey
Parsons, Susan K.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[43] Association Between Treatment Adherence and Response Among Patients With Chronic Myeloid Leukemia (CML) Receiving First-Line TKIs In The Community Setting
Di Bella, Nicholas J.
Bhowmik, Debajyoti
Bhor, Menaka
Yap, Mark
Middlebrook, Brooke
Rembert, Debra
Dhanda, Rahul
Cain, Zachary
Okoro, Tony
Bolinder, Bjorn
Jabbour, Elias J.
BLOOD, 2013, 122 (21)
[44] Treatment patterns and characteristics of acute promyelocytic leukemia (APL) patients receiving arsenic trioxide (ATO) therapy in a real-world setting.
Tang, Boxiong
Gabriel, Susan
Zhou, Jifang
Pathak, Ashutosh K.
Irwin, Debra
Riehle, Ellen
Lo-Coco, Francesco
Tallman, Martin S.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[45] Factors Associated with Upadacitinib Persistence and Risk Minimization Measures in Patients with Rheumatic Diseases in a Real-world Setting. UPAreal Study
Garcia Dorta, Alicia
Rodriguez-Regalado, Cristina
Hernandez-Martin, Andrea
Pena-Montelongo, Sonia
Martinez-Gonzalez, Cristina
Naveda-Gonzalez, Elena
Gonzalez-Davila, Enrique
Diaz-Gonzalez, Federico
Hernandez-Hernandez, Vanesa
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1090 - 1092
[46] US real-world immunotherapy-based treatment patterns and clinical outcomes of advanced NSCLC (aNSCLC) patients in the first-line setting
Bittoni, M. A.
Divan, H. A.
Krishna, A.
Gosset, S.
Carbone, D. P.
ANNALS OF ONCOLOGY, 2021, 32 : S1416 - S1416
[47] Real-World Treatment Patterns and Outcomes Among Patients with Basal Cell Carcinoma Following First-Line Hedgehog Inhibitor Discontinuation
Lance Cowey
Chieh-I. Chen
Kathleen M. Aguilar
Kalatu Davies
Patrick R. LaFontaine
Matthew G. Fury
Timothy Bowler
Asieh Golozar
Jessica J. Jalbert
Dermatology and Therapy, 2022, 12 : 1211 - 1224
[48] Real-World Treatment Patterns and Outcomes Among Patients with Basal Cell Carcinoma Following First-Line Hedgehog Inhibitor Discontinuation
Cowey, Lance
Chen, Chieh-, I
Aguilar, Kathleen M.
Davies, Kalatu
LaFontaine, Patrick R.
Fury, Matthew G.
Bowler, Timothy
Golozar, Asieh
Jalbert, Jessica J.
DERMATOLOGY AND THERAPY, 2022, 12 (05) : 1211 - 1224
[49] Real-world treatment (Tx) sequences and time to discontinuation (rwTTD) in the first-line (1L) metastatic castration-resistant prostate cancer (mCRPC) setting.
Smyth, Emily Nash
Whipple, Samuel
Guinter, Mark
Haddad, Nadine
Piao, Wenxian
Cui, Zhanglin Lin
Balar, Arjun Vasant
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 55 - 55
[50] Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax plus Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors
Ravelo, Arliene
Patel, Achal
To, Tu My
Li, Sophia S.
Huntington, Scott
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S345 - S345

← 1 2 3 4 5 →